PMID- 18495895
OWN - NLM
STAT- MEDLINE
DCOM- 20080626
LR  - 20211020
IS  - 1529-2401 (Electronic)
IS  - 0270-6474 (Print)
IS  - 0270-6474 (Linking)
VI  - 28
IP  - 21
DP  - 2008 May 21
TI  - Postsynaptic action of brain-derived neurotrophic factor attenuates alpha7 
      nicotinic acetylcholine receptor-mediated responses in hippocampal interneurons.
PG  - 5611-8
LID - 10.1523/JNEUROSCI.5378-07.2008 [doi]
AB  - Nicotinic mechanisms acting on the hippocampus influence attention, learning, and 
      memory and constitute a significant therapeutic target for many 
      neurodegenerative, neurological, and psychiatric disorders. Here, we report that 
      brain-derived neurotrophic factor (BDNF) (1-100 ng/ml), a member of the 
      neurotrophin gene family, rapidly decreases alpha7 nicotinic acetylcholine 
      receptor responses in interneurons of the hippocampal CA1 stratum radiatum. Such 
      effect is dependent on the activation of the TrkB receptor and involves the actin 
      cytoskeleton; noteworthy, it is compromised when the extracellular levels of the 
      endogenous neuromodulator adenosine are reduced with adenosine deaminase (1 U/ml) 
      or when adenosine A(2A) receptors are blocked with SCH 58261 
      (2-(2-furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine) 
      (100 nm). The intracellular application of U73122 
      (1-[6[[(17beta)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione) 
      (5 mum), a broad-spectrum inhibitor of phospholipase C, or GF 109203X 
      (bisindolylmaleimide I) (2 mum), a general inhibitor of protein kinase C 
      isoforms, blocks BDNF-induced inhibition of alpha7 nicotinic acetylcholine 
      receptor function. Moreover, in conditions of simultaneous intracellular dialysis 
      of the fast Ca(2+) chelator BAPTA (10 mm) and removal of extracellular Ca(2+) 
      ions, the inhibitory action of BDNF is further prevented. The present findings 
      disclose a novel target for rapid actions of BDNF that might play important roles 
      on synaptic transmission and plasticity in the brain.
FAU - Fernandes, Catarina C
AU  - Fernandes CC
AD  - Institute of Pharmacology and Neurosciences, Faculty of Medicine and Unit of 
      Neurosciences, Institute of Molecular Medicine, University of Lisbon, 1649-028 
      Lisbon, Portugal. cfernandes@fm.ul.pt
FAU - Pinto-Duarte, Antonio
AU  - Pinto-Duarte A
FAU - Ribeiro, Joaquim Alexandre
AU  - Ribeiro JA
FAU - Sebastiao, Ana M
AU  - Sebastiao AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Neurosci
JT  - The Journal of neuroscience : the official journal of the Society for 
      Neuroscience
JID - 8102140
RN  - 0 
      (5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Bungarotoxins)
RN  - 0 (Chelating Agents)
RN  - 0 (Chrna7 protein, rat)
RN  - 0 (Excitatory Amino Acid Agonists)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Receptors, Nicotinic)
RN  - 0 (Sodium Channel Blockers)
RN  - 0 (Triazoles)
RN  - 0 (alpha7 Nicotinic Acetylcholine Receptor)
RN  - 4368-28-9 (Tetrodotoxin)
RN  - 526U7A2651 (Egtazic Acid)
RN  - 6OTE87SCCW (6-Cyano-7-nitroquinoxaline-2,3-dione)
RN  - 76326-31-3 (2-amino-5-phosphopentanoic acid)
RN  - HG18B9YRS7 (Valine)
RN  - K22DDW77C0 (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid)
RN  - N9YNS0M02X (Acetylcholine)
SB  - IM
MH  - 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology
MH  - Acetylcholine/pharmacology
MH  - Analysis of Variance
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/*pharmacology
MH  - Bungarotoxins/pharmacology
MH  - Chelating Agents/pharmacology
MH  - Drug Interactions
MH  - Egtazic Acid/analogs & derivatives/pharmacology
MH  - Excitatory Amino Acid Agonists/pharmacology
MH  - Excitatory Postsynaptic Potentials/*drug effects/physiology
MH  - Hippocampus/*cytology
MH  - In Vitro Techniques
MH  - Interneurons/*drug effects/physiology
MH  - Male
MH  - Patch-Clamp Techniques/methods
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Pyrimidines/pharmacology
MH  - Rats
MH  - Receptors, Nicotinic/*physiology
MH  - Sodium Channel Blockers/pharmacology
MH  - Tetrodotoxin/pharmacology
MH  - Triazoles/pharmacology
MH  - Valine/analogs & derivatives/pharmacology
MH  - alpha7 Nicotinic Acetylcholine Receptor
PMC - PMC6670615
COIS- The authors declare no competing financial interests.
EDAT- 2008/05/23 09:00
MHDA- 2008/06/27 09:00
PMCR- 2008/11/21
CRDT- 2008/05/23 09:00
PHST- 2008/05/23 09:00 [pubmed]
PHST- 2008/06/27 09:00 [medline]
PHST- 2008/05/23 09:00 [entrez]
PHST- 2008/11/21 00:00 [pmc-release]
AID - 28/21/5611 [pii]
AID - 3355237 [pii]
AID - 10.1523/JNEUROSCI.5378-07.2008 [doi]
PST - ppublish
SO  - J Neurosci. 2008 May 21;28(21):5611-8. doi: 10.1523/JNEUROSCI.5378-07.2008.